1 month to go before news, page-7

At a guess I would say 50/50, more trials need to be done but it appears the drug works just the dosage and method needs to be fine tuned.

Considering xtolls potential, considering how hard these players want to get on board and considering what big pharmas are paying for companies like Xtoll in the RA space I think 50/50 is reasonable odds here.

If Novo aren't interested thats not the end of the world either obviously, with CBZ in discussions with other players.

If Novo do take up their option my guess is we will see $1 level.